PASS of Paediatric Patients Initiating Selumetinib

Trial Identifier: D1346R00004
Sponsor: AstraZeneca
Start Date: May 2022
Primary Completion Date: May 2028
Study Completion Date: May 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Austria Wien, Austria
France Amiens, France
France Angers, France
France Bordeaux, France
France Lille, France
France Lyon, France
France Marseille, France
France Paris, France
France Rennes, France
France STRASBOURG, France
France Toulouse, France
France Tours, France
France Villejuif Cedex, France
Germany Dresden, Germany
Germany Duisburg, Germany
Germany Hamburg, Germany
Germany München, Germany
Germany Tubingen, Germany
Israel Petach Tikva, Israel
Israel Ramat Gan, Israel
Israel Tel Aviv-Yafo, Israel
Italy Firenze, Italy
Italy Genova, Italy
Italy Milano, Italy
Italy Padova, Italy
Italy Pavia, Italy
Italy Roma, Italy
Italy Torino, Italy
Italy Trieste, Italy
Netherlands Rotterdam, Netherlands
Portugal Lisboa, Portugal
Portugal Porto, Portugal
Spain Barcelona, Spain
Spain Esplugues de Llobregat, Spain
Spain Madrid, Spain
Spain Malaga, Spain
Spain Santiago de Compostela, Spain
Spain Sevilla, Spain
Switzerland Basel, Switzerland
Switzerland Bern, Switzerland
Switzerland Lausanne, Switzerland
Switzerland St. Gallen, Switzerland
UK London, UK
UK Manchester, UK
UK Newcastle, UK